본문 바로가기

Senescence marker protein 30 deficiency increases Parkinson's pathology by impairing astrocyte activation

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q1
저널
NEUROBIOLOGY OF AGING34(4) · pp.1177 · 2013
피인용
Web of Science 15
JCR IF
JCR 2012 6.166
ISSN
0197-4580

저자

  1. 김현수제1저자부산대학교, 약학대학, 약학부, KO
  2. Son, Tae Gen동남권원자력의학원, Res Ctr, Dept Expt Radiat, KO
  3. 박희라부산대학교, 약학대학, 약학부, 약학전공, KO
  4. 이용현부산대학교, 약학대학, 약학부, 제약학전공, KO
  5. 정연진부산대학교, 약학대학, 약학부, 제약학전공, KO
  6. Ishigami, AkihitoTokyo Metropolitan Inst Gerontol, JA
  7. 이재원교신저자부산대학교, 약학대학, 약학부, KO

초록

Senescence marker protein 30 (SMP30) was recently identified as gluconolactonase, which is involved in vitamin C (VC) biosynthesis. Therefore, the antioxidant property of SMP30 is thought to be mediated by its gluconolactonase function. However, pathologic effects of SMP30 deficiency independent of VC biosynthesis have not been studied in models of neurodegenerative diseases. In the present study, we evaluated the effect of SMP30 deficiency on Parkinson's disease (PD) in SMP30 knockout (KO) mice. Wild type and SMP30 KO mice supplemented with VC were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Our results showed that MPTP-induced dopaminergic neuronal loss and motor function impairment were more significant in the SMP30 KO mice. Reactive oxygen species generation and microglia activation were higher in MPTP-treated SMP30 KO mice. However, SMP30 deficiency mitigated MPTP-induced astrocyte activation and glia-derived neurotrophic factor production. Cultures of astrocytes recovered from wild type and SMP30 KO mice revealed that SMP30 deficiency abolished 1-methyl-4-phenyl-pyridinium-induced astroglial activation by blocking the extracellular signal-regulated kinase pathway. Taken together, our findings demonstrate for the first time that SMP30 deficiency increases the severity of PD and suggest a beneficial role of SMP30 in protective astrocyte activation in response to neurodegeneration. The present study shows that modulation of astrocytic SMP30 can be a promising target for treating PD. (C) 2013 Elsevier Inc. All rights reserved.

키워드

AgingNeurodegenerative diseasesVitamin C biosynthesisOxidative stressSMP30/GNL KNOCKOUT MICEMPTP MOUSE MODELHEP G2 CELLSOXIDATIVE STRESSHUNTINGTONS-DISEASERAT-LIVERBRAINSTRATEGIESNEURODEGENERATIONTHERAPY

식별자

WoS UID
000314708000019